There are three main services that dentists providing care for temporomandibular disorders (TMDs) actually provide. They are to diminish pain, improve function, and diminish negative quality of lif...

2012-01-01·Magnetic Resonance in Medicine2区 · 医学

Automated detection and characterization of SPIO‐labeled cells and capsules using magnetic field perturbations

2区 · 医学

Article

作者: Aravind Arepally ; T. Kevin Hitchens ; Wesley D. Gilson ; Parker H. Mills ; Joe D. Thompson ; Eric T. Ahrens ; Thomas Link ; Jeff W. M. Bulte ; John A. Melick ; Patrick M. Kochanek ; Chien Ho ; Qing Ye ; Clifford R. Weiss ; Lesley M. Foley

AbstractUnderstanding how individual cells behave inside living systems will help enable new diagnostic tools and cellular therapies. Superparamagnetic iron oxide particles can be used to label cells and theranostic capsules for noninvasive tracking using MRI. Contrast changes from superparamagnetic iron oxide are often subtle relative to intrinsic sources of contrast, presenting a detection challenge. Here, we describe a versatile postprocessing method, called Phase map cross‐correlation Detection and Quantification (PDQ), that automatically identifies localized deposits of superparamagnetic iron oxide, estimating their volume magnetic susceptibility and magnetic moment. To demonstrate applicability, PDQ was used to detect and characterize superparamagnetic iron oxide‐labeled magnetocapsules implanted in porcine liver and suspended in agarose gel. PDQ was also applied to mouse brains infiltrated by MPIO‐labeled macrophages following traumatic brain injury; longitudinal, in vivo studies tracked individual MPIO clusters over 3 days, and tracked clusters were corroborated in ex vivo brain scans. Additionally, we applied PDQ to rat hearts infiltrated by MPIO‐labeled macrophages in a transplant model of organ rejection. PDQ magnetic measurements were signal‐to‐noise ratio invariant for images with signal‐to‐noise ratio > 11. PDQ can be used with conventional gradient‐echo pulse sequences, requiring no extra scan time. The method is useful for visualizing biodistribution of cells and theranostic magnetocapsules and for measuring their relative iron content. Magn Reson Med, 2011. © 2011 Wiley‐Liss, Inc.

2006-02-01·Chemico-Biological Interactions2区 · 医学

Tumor-promoting activity of p-hydroxybenzenediazonium is accelerated in Mg-deficient rats

2区 · 医学

Article

作者: Juan Llopis ; Pilar Aranda ; María del Carmen Cabeza ; María del Pilar Gutiérrez ; Antonio Zarzuelo ; Bartolome Quintero ; Elena Planells ; Javier Esquivias ; Cristina Sánchez

Tumor-promoting activity caused by the short-term administration of p-hydroxybenzenediazonium (PDQ) has been assayed in rats fed on a Mg-deficient diet as a reference model versus rats fed on a standard diet as controls. For 5 weeks groups of 20 rats, fed either on the Mg-deficient or standard diet, were treated simultaneously with PDQ. A group of 10 Mg-deficient rats remained untreated. Topical application of PDQ was followed by the appearance of macroscopic alterations in the skin, which were more evident in the Mg-deficient rats. No deaths occurred during the treatment. After 5 weeks' PDQ treatment the rats were killed and histological analyses were made. Tissues from the skin, liver, heart, kidney, lung and thymus were screened by conventional staining methods. Both the PDQ-treated Mg-deficient and PDQ-treated control rats presented tissue lesions, although to a different extent. The untreated Mg-deficient rats showed no such lesions. Mg-deficient rats treated with PDQ developed significant incipient fibrosarcomas (p<0.05) and extended hyperplasia (p<0.001), particularly in the skin, accompanied by a significant increase in the thickness of collagen (mean value: 445.4+/-47.2microm, p<0.05) compared to the control PDQ-treated group (mean values: 258.7+/-36.4microm). The overall results provide objective proof of tumor-promoting activity after 5 weeks' treatment with PDQ. Such a fast response is interpreted as being linked to the increased vulnerability of the membrane caused by Mg deficiency, which would more readily facilitate the toxic activity of p-hydroxybenzenediazonium ions.

项与 PDQ 滴丸(华康药业) 相关的新闻（医药）

2025-03-11

·赞Med

改善帕金森病患者生活质量，MAO-B抑制剂效果显著！

点击上方“蓝字”关注我们吧！帕金森病（PD）不仅影响患者的运动功能，还会对其生活质量造成严重影响。近年来，单胺氧化酶B型（MAO-B）抑制剂作为PD治疗的重要药物，其在改善患者生活质量方面的作用备受关注。近日，一项发表在《Behavioural Brain Research》杂志上的系统综述和meta分析《Effects of MAO B inhibitors in life quality of Parkinson’s disease patients: A systematic review and meta analysis》1，为我们提供了新的循证医学证据。研究方法该研究通过在PubMed、Embass 和 Cochrane Library 数据库中检索了接受MAO-B抑制剂治疗的 PD 患者的随机对照试验，通过39项帕金森病生活质量问卷（PDQ-39）、健康调查简表（SF）、世界卫生组织生活质量量表（WHOQOL）、PDQUALIF、欧洲生活质量五维量表（EQ-5D）和8项帕金森病生活质量问卷（PDQ-8）等相关量表评估司来吉兰、雷沙吉兰、唑尼沙胺和沙非胺（既往又称沙芬酰胺）四种MAO-B抑制剂对患者生活质量的影响。研究结果最后16 项研究（4734例PD患者）符合系统评价条件（表 1），12 项研究被纳入最终荟萃分析。在当前系统评价和荟萃分析纳入的研究中，10 项是关于雷沙吉兰，6 项是关于沙非胺。尚无司来吉兰和唑尼沙胺的研究符合评价标准。10 项雷沙吉兰试验的研究人群来自亚洲、北美和欧洲国家。大多数雷沙吉兰研究的日剂量为 1 mg。6项沙非胺试验中有一半是多中心试验，并在多个国家进行，包括欧洲国家、亚太地区和北美。所有研究都包括了每日剂量100 mg沙非胺，3项研究评估了 50 mg沙非胺的效果。表1 评估量表生活质量评估工具包括 PDQ-39 、 EQ-5D 和 PDQUALIF。其中PDQ-39 是研究中使用最广泛的，所有 12 项有可用数据的研究都纳入了 meta 分析。PDQ-39 评估患者生活质量的不同领域，包括身体活动、日常生活行为、精神健康、病耻感、社会支持、认知、交流和身体不适。使用 PDQ-39 工具的 12 项研究中有 7 项具有具体不同的领域评估数据，并被纳入比较（表 2 ）表2 接受 MAO-B 抑制剂治疗的PD患者在生活质量方面有所改善荟萃分析纳入了 12 项采用 PDQ-39 的研究，其中 3 项检查了研究药物的两种每日剂量水平。结果提示与安慰剂组相比，接受 MAO-B 抑制剂治疗的患者在 PDQ-39 评估的生活质量方面有所改善（SMD: -0.26, 95 % CI: [-0.49, -0.04], P = 0.02 )（图 1）。此外，荟萃分析也纳入了 3 项采用 EQ-5D 效用指数的研究和 2 项使用 EQ-5D VAS 的研究。与安慰剂组相比，接受 MAO-B 抑制剂治疗的患者在EQ-5D评估的生活质量方面表现出更好的水平（EQ-5D 效用指数 SMD: 0.05, 95 % CI: [0.03, 0.08], P < 0.0001; EQ-5D VAS SMD: 5.18, 95 % CI: [2.51,7.85] , P = 0.0001）（图 1）。图1接受MAO-B抑制剂治疗患者相比安慰剂生活质量量表相对于基线变化的森林图荟萃分析中还包括 7 项具体 PDQ-39 领域数据的研究，1 项研究评估了两种剂量水平对生活质量的影响。与安慰剂组相比，接受 MAO-B 抑制剂治疗的患者在身体活动（SMD: -3.02, 95 % CI: [-4.64, -1.40], P = 0.0003）、日常生活行为（SMD: -5.75, 95 % CI: [-7.33, -4.16], P < 0.00001）、精神健康（SMD: -3.65, 95 % CI: [-5.00, -2.30], P < 0.00001）、病耻感（SMD: -2.21, 95 % CI: [-3.76, -0.67], P = 0.005）、交流（SMD: -1.45, 95 % CI: [-2.80, -0.10], P = 0.03）和身体不适（SMD: -2.40, 95 % CI: [-4.01, -0.79], P = 0.004）等领域表现更好，而在社会支持（SMD: -0.56, 95 % CI: [-1.86, 0.74], P = 0.40）和认知（SMD: -0.87, 95 % CI: [-2.40, 0.67], P = 0.27) 领域无显著差异。亚组分析关于亚组分析，仅 PDQ-39 研究的数据符合分析（表 3 ）。其中雷沙吉兰（0.5 mg剂量组）和沙非胺（50 mg剂量组）患者的数量不足以完成亚组分析。研究药物和每日剂量水平的亚组分析显示，沙非胺全剂量组（SMD: -0.44, 95 % CI: [-0.80, -0.07], P = 0.02）和 100 mg沙非胺组（SMD: -0.52, 95 % CI: [-1.04, -0.01], P = 0.05）的 PDQ-39 改善结果更好。对于按偏倚风险划分的亚组分析，低偏移风险组的研究显示 PDQ-39 存在显著差异（SMD: -0.21, 95 % CI: [-0.30, -0.11], P < 0.0001）。而在雷沙吉兰全剂量组、1 mg 雷沙吉兰组以及偏倚风险不明确的亚组中未发现显著差异。表 3 安全性关于安全性，MAO-B 抑制剂组不良事件的发生率略高于安慰剂组（RR: 1.21 95 % CI: [1.04, 1.40]，P = 0.01）。结语目前的系统综述和meta分析表明，MAO-B抑制剂，尤其是沙非胺（相比雷沙吉兰，沙非胺除MAO-B 机制以外，还可以影响谷氨酸的释放）可有效改善 PD 患者的生活质量。与安慰剂相比，接受 MAO-B 抑制剂治疗的患者生活质量（认知和社会支持领域除外）有所改善。参考文献 1. Liu X, Su J, Zhang J, Li Z, Huang K, Lin D, Tao E. Effects of MAO B inhibitors in life quality of Parkinson's disease patients: A systematic review and meta analysis. Behav Brain Res. 2025 Mar 5;480:115410. 提示：本材料仅供医疗卫生专业人士进行医学科学交流，不用于推广目的。

临床结果临床研究

100 项与 PDQ 滴丸(华康药业) 相关的药物交易

登录后查看更多信息